Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Global Initiative Orders 120 Million Abbott, SD Biosensor COVID-19 Rapid Antigen Tests

Executive Summary

Tests will be priced at under $5 each for low- and middle-income countries.

You may also be interested in...



Abbott Receives US Authorization For First 'Virtually Guided' At-Home Rapid Test

Abbott plans to deliver 30 million BinaxNOW prescription, at-home rapid tests in the first quarter of 2021; 90 million more in the second quarter.

US Government Awards $481M To Help Cue Health Expand COVID-19 Test Production

Cue’s point-of-care molecular test earned an FDA emergency use authorization in June.

Global Response To COVID-19 Promises Equitable Access, Independent WHO Probe

A resolution at the latest World Health Assembly meeting on providing universal and equitable access to COVID-19 technologies, medicines and vaccines has been adopted, along with an agreement to review the World Health Organization’s response to the crisis.

Topics

Related Companies

UsernamePublicRestriction

Register

MT142808

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel